Inhibition of p53 inhibitors: progress, challenges and perspectives

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• The p53 protein is a critical tumor suppressor frequently inactivated in various cancers.
• Inactivation occurs through mutations or overexpression of negative regulators like MDM2 and MDMX.
• Restoring p53 activity is a validated strategy for cancer prevention and treatment.

Purpose of the Study:

• To review recent advancements in small molecules designed to restore wild-type p53 tumor suppressor function.
• To discuss the clinical progress of these p53-restoring agents.
• To explore diverse p53-mediated anti-cancer mechanisms, including non-canonical activities like immune response regulation.

Main Methods:

• Review of current scientific literature on p53 reactivation strategies.
• Analysis of preclinical and clinical data for small molecules targeting p53 pathway.
• Discussion of the molecular mechanisms underlying p53's tumor suppressive roles.

Main Results:

• Small molecules capable of restoring wild-type p53 function have shown efficacy in preclinical models.
• Several compounds are progressing through clinical evaluation for various cancer types.
• p53's role extends beyond canonical functions, encompassing regulation of the immune system.

Conclusions:

• Targeting p53 inhibitors represents a highly promising anti-cancer therapeutic strategy.
• Ongoing research and clinical trials are crucial for overcoming existing limitations and concerns.
• Reactivation of p53 holds significant potential for effective cancer therapy.